Simon Gollins

8.3k total citations · 2 hit papers
84 papers, 4.4k citations indexed

About

Simon Gollins is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Simon Gollins has authored 84 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 49 papers in Surgery and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simon Gollins's work include Colorectal Cancer Surgical Treatments (32 papers), Colorectal and Anal Carcinomas (31 papers) and Colorectal Cancer Treatments and Studies (23 papers). Simon Gollins is often cited by papers focused on Colorectal Cancer Surgical Treatments (32 papers), Colorectal and Anal Carcinomas (31 papers) and Colorectal Cancer Treatments and Studies (23 papers). Simon Gollins collaborates with scholars based in United Kingdom, Netherlands and United States. Simon Gollins's co-authors include J. S. Porterfield, Arthur Sun Myint, David Sebag‐Montefiore, Mark Saunders, Stephen Falk, Tim Maughan, David Cunningham, S. Susnerwala, Andrew G. Renehan and Rob Glynne‐Jones and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Simon Gollins

84 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis

2015 504 citations Simon Gollins, Andrew Maw et al. The Lancet Oncology profile →
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

2013 459 citations Rob Glynne‐Jones, Helen Meadows et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Gollins United Kingdom	34	2.5k	2.2k	1.6k	363	334	84	4.4k
Catherine D. Cooksley United States	28	1.8k 0.7×	725 0.3×	1.8k 1.2×	501 1.4×	204 0.6×	40	3.7k
Rungsun Rerknimitr Thailand	33	2.1k 0.8×	2.6k 1.2×	2.5k 1.6×	521 1.4×	91 0.3×	298	4.7k
Shomik Sengupta Australia	32	2.3k 0.9×	1.5k 0.7×	2.1k 1.3×	301 0.8×	101 0.3×	175	4.9k
Brittany L. Murphy United States	21	1.3k 0.5×	775 0.3×	933 0.6×	667 1.8×	169 0.5×	74	3.6k
Stephen A. Geller United States	32	1.4k 0.6×	1.1k 0.5×	833 0.5×	1.1k 3.0×	253 0.8×	127	4.2k
Heidrun Rotterdam United States	33	922 0.4×	2.7k 1.2×	1.5k 0.9×	1.2k 3.4×	162 0.5×	75	4.4k
Manuel Zorzi Italy	36	2.5k 1.0×	1.8k 0.8×	1.2k 0.7×	2.5k 6.9×	114 0.3×	163	5.1k
Shinichiro Mori Japan	29	1.2k 0.5×	677 0.3×	741 0.5×	664 1.8×	150 0.4×	189	2.8k
James E. Allison United States	30	1.7k 0.7×	938 0.4×	1.3k 0.8×	1.5k 4.0×	274 0.8×	47	3.7k
Graeme R. Russ Australia	38	1.0k 0.4×	1.3k 0.6×	421 0.3×	717 2.0×	672 2.0×	132	4.7k

Countries citing papers authored by Simon Gollins

Since Specialization

Citations

This map shows the geographic impact of Simon Gollins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Gollins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Gollins more than expected).

Fields of papers citing papers by Simon Gollins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Gollins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Gollins. The network helps show where Simon Gollins may publish in the future.

Co-authorship network of co-authors of Simon Gollins

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Gollins. A scholar is included among the top collaborators of Simon Gollins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Gollins. Simon Gollins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lafarge, Maxime W., Enric Domingo, Korsuk Sirinukunwattana, et al.. (2024). Image-based consensus molecular subtyping in rectal cancer biopsies and response to neoadjuvant chemoradiotherapy. npj Precision Oncology. 8(1). 89–89. 9 indexed citations

Hanna, Catherine, Finbar Slevin, Ane Appelt, et al.. (2021). Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020. Clinical Oncology. 33(4). 214–223. 19 indexed citations

Mukherjee, Somnath, Chris Hurt, Ganesh Radhakrishna, et al.. (2021). Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer. 153. 153–161. 13 indexed citations

Richman, Susan D., Simon Gollins, Peter Stewart, et al.. (2018). Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies. The Journal of Pathology. 245(1). 19–28. 40 indexed citations

Myint, Arthur Sun, F. M. Smith, Simon Gollins, et al.. (2017). Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?. British Journal of Radiology. 90(1080). 20170175–20170175. 36 indexed citations

Hendry, Maggie, Diana Pasterfield, Simon Gollins, et al.. (2017). Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open. 7(6). e015413–e015413. 9 indexed citations

Myint, Arthur Sun, F. M. Smith, Simon Gollins, et al.. (2017). Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience. International Journal of Radiation Oncology*Biology*Physics. 100(3). 565–573. 56 indexed citations

Rao, Christopher, F. M. Smith, Antony P. Martin, et al.. (2017). A Cost-Effectiveness Analysis of Contact X-ray Brachytherapy for the Treatment of Patients with Rectal Cancer Following a Partial Response to Chemoradiotherapy. Clinical Oncology. 30(3). 166–177. 10 indexed citations

Hendry, Maggie, Richard Adams, Mererid Evans, et al.. (2016). Talking about human papillomavirus and cancer: protocol for a patient-centred study to develop scripted consultations. BMJ Open. 6(4). e011205–e011205. 3 indexed citations

10.

Harris, Dean, Kymberley Thorne, Hayley Hutchings, et al.. (2016). Protocol for a multicentre randomised feasibility trial evaluating early Surgery Alone In LOw Rectal cancer (SAILOR). BMJ Open. 6(11). e012496–e012496. 6 indexed citations

11.

Middleton, Gary, Sarah Brown, Catherine Lowe, et al.. (2013). A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer. 49(16). 3507–3516. 19 indexed citations

12.

Crosby, T., Chris Hurt, Stephen Falk, et al.. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology. 14(7). 627–637. 272 indexed citations

13.

Maw, Andrew, et al.. (2013). Does pre-operative chemoradiotherapy cause wound complications after abdominoperineal excision for rectal cancer? An observational study. International Journal of Surgery. 11(5). 395–399. 6 indexed citations

14.

Gwynne, Sarah, Stephen Falk, Simon Gollins, et al.. (2013). Oesophageal Chemoradiotherapy in the UK—Current Practice and Future Directions. Clinical Oncology. 25(6). 368–377. 22 indexed citations

15.

Glynne‐Jones, Rob, David Sebag‐Montefiore, Richard Adams, et al.. (2012). Prognostic factors for recurrence and survival in anal cancer. Cancer. 119(4). 748–755. 59 indexed citations

16.

Morrison, Val, et al.. (2011). Common, important, and unmet needs of cancer outpatients. European Journal of Oncology Nursing. 16(2). 115–123. 66 indexed citations

17.

Adams, Richard, Angela Meade, Michel Seymour, et al.. (2011). Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. The Lancet Oncology. 12(7). 642–653. 177 indexed citations

18.

Gollins, Simon. (2010). Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. Colorectal Disease. 12(s2). 2–24. 11 indexed citations

19.

Rothenberg, Mace L., John V. Cox, Charles Butts, et al.. (2008). Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of Oncology. 19(10). 1720–1726. 156 indexed citations

20.

Cullen, Michael, Neil Steven, Lucinda Billingham, et al.. (2005). Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas. New England Journal of Medicine. 353(10). 988–998. 275 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact